Medicinsk behandling af KOL

Ugeskrift for Laeger

Volumn 175, Issue 18, 2013, Pages 1261-1264

  Vestbo, Jørgen ^a,b,c   Titlestad, Ingrid L ^a,b  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c Respiratory Research Unit   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DELAYED RELEASE FORMULATION; HUMAN; INHALATIONAL DRUG ADMINISTRATION;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-2 RECEPTOR AGONISTS; BRONCHODILATOR AGENTS; CHOLINERGIC ANTAGONISTS; DELAYED-ACTION PREPARATIONS; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84878630469     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Vestbo J, Hurd SS, Agusti AG et al. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease, GOLD executive summary. Am J Respir Crit Care Med 2013;187:347-65.
2. Appleton S, Poole P, Smith B et al. Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease. Cochrane Syst Rev 2006;3:CD001104.
3. Barr RG, Bourbeau J, Camargo CA. Tiotropium for stable chronic obstructive pulmonary disease. Cochrane Syst Rev 2005;2:CD002876.
4. Yang IA, Fong K, Sim EHA et al. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Syst Rev 2007;2: CD002991.
5. Calverley PM, Rabe KF, Goehring UM et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009;374:685-94.
6. Celli BR, Thomas NE, Anderson JA et al. Effect of pharmacotherapy on rate of decline of lung function in COPD: results from the TORCH study. Am J Respir Crit Care Med 2008;178:332-8.
7. Decramer M, Celli B, Kesten S et al. UPLIFT investigators. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet 2009;374:1171-8.
8. Troosters T, Celli B, Lystig T et al. On behalf of the UPLIFT investigators. Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial. Eur Respir J 2010;36:65-73.
9. Tashkin DP, Celli B, Senn S et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359:1543-54.
10. Calverley PMA, Anderson JA, Celli B et al. On behalf of the TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89.
11. Nannini LJ, Cates CJ, Lasserson TJ et al. Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Syst Rev 2007;4:CD003794.
12. Celli B, Decramer M, Kesten S et al. On behalf of the UPLIFT study investigators. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;180:948-55.
13. Boyd G, Morice AH, Pounsford JC et al. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur Respir J 1997;10:815-21.
14. Dahl R, Greefhorst LAPM, Nowak D et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:778-84.
15. Calverley PMA, Anderson JA, Celli B et al. On behalf of the TORCH investigators. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax 2010;65:719-25.
16. Celli B, Decramer M, Leimer I et al. Cardiovascular safety of tiotropium in patients with COPD. Chest 2010;137:20-30.
17. Singh S, Loke YK, Enright PL et al. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials. BMJ 2011;342:d3215.
18. Anzueto A. Impact of exacerbations on COPD. Eur Respir Rev 2010;19:113-8.
19. Hurst JR, Vestbo J, Anzueto A et al. For the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010;363:1128-38.
20. Jenkins CR, Jones PW, Calverley PMA et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res 2009;10:59.
21. Wedzicha JA, Decramer M, Seemungal TAR. The role of bronchodilator treatment in the prevention of exacerbations of COPD. Eur Respir J 2012; 40:1545-54.
22. Vogelmeier C, Hederer B, Glaab T et al. POET-COPD Investigators. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011;364:1093-103.
23. Nannini LJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta2-agonist in one inhaler versus long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Syst Rev 2012;9:CD006829.
24. Vestbo J, Anderson JA, Calverley PMA et al. Bias due to withdrawal in long-term randomised trials in COPD: evidence from the TORCH study. Clin Respir J 2011;5:44-9.
25. Fabbri LM, Calverley PM, Izquierdo-Alonso JL et al. Roflumilast in moderate-tosevere chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 2009;374:695-703.
26. Albert RK, Connett J, Bailey WC et al. For the COPD Clinical Research Network. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011;365:689-98.
27. Jespersen MJ, Mygind LH, Vestbo J et al. Sparsom effekt af langtidsbehandling med makrolider ved kronisk obstruktiv lungesygdom. Ugeskr Læger 2012;174:2-5.
28. Davies L, Angus RM, Calverley PM. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet 1999;354:456-60.
29. Niewoehner DE, Erbland ML, Deupree RH et al. Department of Veterans Affairs Cooperative Study Group. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1999;340:1941-7.
30. Thompson WH, Nielson CP, Carvalho P et al. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am J Respir Crit Care Med 1996;154:407-12.